{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:07:49Z","timestamp":1793419669405,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jconrel.2023.06.027","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T16:49:32Z","timestamp":1688057372000},"page":"285-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route"],"prefix":"10.1016","volume":"360","author":[{"given":"Haruka","family":"Takata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Yamade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal E.","family":"Elsadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif E.","family":"Emam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Ishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.06.027_bb0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1359-0294(00)00090-X","article-title":"Liposome application: problems and prospects","volume":"6","author":"Barenholz","year":"2001","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0010","first-page":"81","article-title":"A review on phospholipids and their main applications in drug delivery systems","volume":"10","author":"Li","year":"2015","journal-title":"Asian J. Pharmaceut. Sci."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2020.06.022","article-title":"Recent advancements in liposome technology","volume":"156","author":"Filipczak","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1023\/A:1020134521778","article-title":"Liposome clearance","volume":"22","author":"Ishida","year":"2002","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0025","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0005-2736(91)90201-I","article-title":"Pharmacokinetics of stealth versus conventional liposomes: effect of dose","volume":"1068","author":"Allen","year":"1991","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembrane."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0030","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.1073\/pnas.88.24.11460","article-title":"Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy","volume":"88","author":"Papahadjopoulos","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0014-5793(90)81016-H","article-title":"Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes","volume":"268","author":"Klibanov","year":"1990","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0045","article-title":"Clinical implications of molecular PEGylation on therapeutic proteins","volume":"8","author":"Magharla","year":"2017","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0050","unstructured":"NIH, Search of: PEGylated - List Results - ClinicalTrials.gov, in."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/bc700333s","article-title":"Novel prodrugs of SN38 using multiarm poly (ethylene glycol) linkers","volume":"19","author":"Zhao","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0060","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0065","first-page":"270","article-title":"Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia a treatment","volume":"116","author":"Mei","year":"2010","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0070","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000233309","article-title":"Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins","volume":"70","author":"Richter","year":"1983","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0080","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","volume":"292","author":"Dams","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-3659(02)00462-5","article-title":"Accelerated clearance of PEGylated liposomes in rats after repeated injections","volume":"88","author":"Ishida","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2006.01.005","article-title":"Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes","volume":"112","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics3010001","article-title":"Anti-PEG IgM response against PEGylated liposomes in mice and rats","volume":"3","author":"Ichihara","year":"2010","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijpharm.2014.09.047","article-title":"Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin","volume":"476","author":"Suzuki","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0110","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.drudis.2014.08.015","article-title":"Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics","volume":"19","author":"Verhoef","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0115","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0120","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","article-title":"Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0125","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108748","article-title":"Anaphylaxis associated with the mRNA COVID-19 vaccines: approach to allergy investigation","volume":"227","author":"Erdeljic Turk","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0135","article-title":"Pseudo-anaphylactic reactions to Pfizer BNT162b2 vaccine: report of 3 cases of anaphylaxis post Pfizer BNT162b2 vaccination","volume":"9","author":"Lim","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0140","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.anai.2021.03.004","article-title":"Hypersensitivity to different polyethylene glycol-containing products","volume":"126","author":"Khalid","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Abu Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0150","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5507\/bp.2019.010","article-title":"Nanodrugs used in cancer therapy","volume":"163","author":"Kopeckova","year":"2019","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0005-2736(94)90004-3","article-title":"Factors influencing the retention and chemical stability of poly (ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles","volume":"1195","author":"Parr","year":"1994","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembrane."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0160","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0165","article-title":"An evidence based perspective on mRNA-SARS-CoV-2 vaccine development","volume":"26","author":"Wang","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Therapy-Nucleic Acids"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0175","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/B978-0-12-800148-6.00004-3","article-title":"Lipid nanoparticles for short interfering RNA delivery","volume":"88","author":"Leung","year":"2014","journal-title":"Adv. Genet."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0180","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1021\/js980235x","article-title":"Application of surface-coated liposomes for oral delivery of peptide: effects of coating the liposome\u2019s surface on the GI transit of insulin","volume":"88","author":"Iwanaga","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0005-2736(93)90115-G","article-title":"Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection","volume":"1150","author":"Allen","year":"1993","journal-title":"Biochim. Biophys. Acta (BBA)-Biomembrane."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0190","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1023\/A:1012145410859","article-title":"Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly (ethyleneglycol)","volume":"14","author":"Oussoren","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0195","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2010.08.026","article-title":"Peritoneal retention of liposomes: effects of lipid composition, PEG coating and liposome charge","volume":"148","author":"Dadashzadeh","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0200","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2011.12.017","article-title":"PEGylated cationic liposomes robustly augment vaccine-induced immune responses: role of lymphatic trafficking and biodistribution","volume":"159","author":"Zhuang","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0205","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.taap.2014.03.002","article-title":"Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs","volume":"277","author":"Hashimoto","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0210","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jconrel.2006.08.001","article-title":"Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes","volume":"115","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0215","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0220","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijpharm.2010.03.022","article-title":"T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes","volume":"392","author":"Koide","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0225","doi-asserted-by":"crossref","first-page":"803","DOI":"10.4049\/jimmunol.172.2.803","article-title":"Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells","volume":"172","author":"Attanavanich","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0230","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.4049\/jimmunol.162.12.7198","article-title":"IgMhighCD21high lymphocytes enriched in the splenic marginal zone generate effector cells more rapidly than the bulk of follicular B cells","volume":"162","author":"Oliver","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0235","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1084\/jem.190.4.471","article-title":"B cell antigen receptor specificity and surface density together determine B-1 versus B-2 cell development","volume":"190","author":"Lam","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0240","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154-155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0245","article-title":"Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines","volume":"1-2","author":"Ju","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23168838","article-title":"Monitoring anti-PEG antibodies level upon repeated lipid nanoparticle-based COVID-19 vaccine administration","volume":"23","author":"Guerrini","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0255","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0260","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1016\/j.vaccine.2022.08.024","article-title":"mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations","volume":"40","author":"Carreno","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0265","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2022.12.039","article-title":"Anti-PEG antibodies before and after a first dose of Comirnaty(R) (mRNA-LNP-based SARS-CoV-2 vaccine)","volume":"354","author":"Bavli","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0270","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.imbio.2012.08.274","article-title":"Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon","volume":"218","author":"Shimizu","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0275","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1248\/bpb.b14-00653","article-title":"Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice","volume":"38","author":"Hashimoto","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0280","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.4049\/jimmunol.171.10.5406","article-title":"Peritoneal cavity B cells are precursors of splenic IgM natural antibody-producing cells","volume":"171","author":"Kawahara","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0285","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/jps.24397","article-title":"Activation of B1a cells in peritoneal cavity by T cell-independent antigen expressed on polymeric micelle","volume":"104","author":"Kim","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121539","article-title":"A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes","volume":"615","author":"El Sayed","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0295","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis. Res. Ther."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0300","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1203165","article-title":"Peginesatide in patients with anemia undergoing hemodialysis","volume":"368","author":"Fishbane","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0305","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1203166","article-title":"Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis","volume":"368","author":"Macdougall","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0310","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2023.01.012","article-title":"Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice","volume":"354","author":"Ibrahim","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0320","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11095-022-03166-5","article-title":"Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size","volume":"39","author":"Di","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.06.027_bb0325","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1111\/all.14794","article-title":"Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation","volume":"76","author":"Klimek","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jconrel.2023.06.027_bb0330","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11357-021-00495-y","article-title":"A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor","volume":"44","author":"Dezsi","year":"2022","journal-title":"Geroscience"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923004005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923004005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:47:51Z","timestamp":1759164471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923004005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":66,"alternative-id":["S0168365923004005"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.027","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}